Zydus Cadila to present new clinical data on Lipagyln at AACE, USA

12 May 2015 Evaluate

Zydus Cadila would be making a presentation on Lipagyln at the American Association of Clinical Endocrinologists (AACE) 24 th Annual Scientific and Clinical Congress to be held from 13 th to 17th of May 2015 at Nashville, Tennesse, USA. Further, the abstract titled ‘9 month safety and efficacy of Saroglitazar in Diabetic Dyslipidemia has been accepted for late breaking presentation at the AACE meeting.

Lipagyln was launched in September 2013 in India for treating Hypertriglyceridemia and Diabetic Dyslipidemia in patients with Type 2 diabetes not controlled by statins. Since then more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians.

Zydus Cadila is an innovation, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines.

Zydus Lifesciences Share Price

913.40 -1.25 (-0.14%)
01-Jan-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.25
Dr. Reddys Lab 1250.80
Cipla 1499.60
Zydus Lifesciences 913.40
Lupin 2101.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×